07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

GlaxoSmithKline, Aspen deal

Aspen exercised an option to acquire GlaxoSmithKline’s thrombosis portfolio in China, including Hong Kong and Macau, India and Pakistan -- the remaining markets not covered under the partners’ 2013 deal. Aspen will now have worldwide...
08:00 , Dec 11, 2014 |  BC Innovations  |  Cover Story

Universal reversal for heparin

Titrating heparin treatment is a balancing act for hematologists trying to control blood coagulation without causing excessive bleeding. A synthetic heparin reversal agent from The University of British Columbia uses a dendritic polymer to neutralize...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Synthetic, universal reversal agent for heparin anticoagulants Synthetic, universal heparin reversal agents could help reduce bleeding complications in patients who use the drug. The synthetic,...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Aspen, Mylan deal

Mylan's Mylan Ireland Ltd. subsidiary acquired U.S. rights to Arixtra fondaparinux and the authorized generic of Arixtra from Aspen. Mylan already sells Arixtra in the U.S. through an interim distribution deal with Aspen, while Apotex...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Lee's Pharmaceutical, ScinoPharm Taiwan deal

Lee's and ScinoPharm partnered to develop, produce and commercialize fondaparinux, travoprost and bimatoprost in China. Fondaparinux is an antithrombotic that selectively inhibits Factor Xa , and travoprost and bimatoprost are prostaglandin analogs. Lee's will have...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline, Columbia University, New York University pharmaceuticals news

As of Sept. 20, five research proposals requesting patient-level data from GlaxoSmithKline under the pharma's January open access initiative have been approved. No request has been rejected. The four remaining submitted proposals are either being...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Aspen, GlaxoSmithKline, Merck sales and marketing update

GlaxoSmithKline said it agreed to sell its injectable anticoagulants Fraxiparine nadroparin and Arixtra fondaparinux and the related manufacturing site in Notre-Dame de Bondeville, France, for £700 million ($1.1 billion) in cash to branded and generic...
01:20 , Oct 2, 2013 |  BC Extra  |  Company News

No rejected requests under GSK transparency initiative

As of Sept. 20, five research proposals requesting patient-level data from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) under the pharma's January open access initiative have been approved. No request has been rejected. The four remaining submitted proposals...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Aspen, GlaxoSmithKline deal

GlaxoSmithKline disclosed in its 2Q13 earnings that branded and generic drug supplier Aspen offered to acquire injectable anticoagulants Fraxiparine nadroparin and Arixtra fondaparinux and the related manufacturing site in Notre-Dame de Bondeville, France, for about...